|
Real-time Estimate
Cboe BZX
12:56:54 2026-10-05 EDT
|
5-day change | 1st Jan Change | ||
| 3.695 USD | +3.21% |
|
-8.50% | +130.75% |
| 08-17 | B. Riley Raises Price Target on MacroGenics to $11 From $9, Keeps Buy Rating | MT |
| 08-13 | MacroGenics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 | CI |
Sales 2025 by Business Segment
Sales 2025 by Geography
Historical Breakdown of Revenue by Business Segments
Net Income: Breakdown by Business Segment
Geographical Revenue Distribution History
| Fiscal Period: December | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
Biological Products | ||||||||||
Developing Innovative Antibody-Based Therapeutics for the Treatment of Cancer | 77.45M | 152M | 58.75M | 150M | 150M | |||||
Total Assets | 335M | 280M | 298M | 262M | 257M | |||||
Interest Expense | - | - | -1.43M | -1.12M | -8.51M | |||||
Income Tax Expense | - | - | - | 944K | -672K | |||||
CAPEX | -6.2M | -3.62M | -1.76M | -3.71M | -1.91M | |||||
EBT | -202M | -120M | -9.06M | -66.02M | -75.29M | |||||
D&A | 11.26M | 11.86M | 9.64M | 7.54M | 7.17M | |||||
Operating Income | -203M | -121M | -168M | -111M | -72.84M | |||||
Net Income | -202M | -120M | -9.06M | -66.97M | -74.62M |
| Fiscal Period: December | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
United States | 77.45M | 152M | 58.75M | 150M | 150M | |||||
Total Assets | 335M | 280M | 298M | 262M | 257M | |||||
Interest Expense | - | - | -1.43M | -1.12M | -8.51M | |||||
Income Tax Expense | - | - | - | 944K | -672K | |||||
D&A | 11.26M | 11.86M | 9.64M | 7.54M | 7.17M | |||||
CAPEX | -6.2M | -3.62M | -1.76M | -3.71M | -1.91M | |||||
Net Income | -202M | -120M | -9.06M | -66.97M | -74.62M | |||||
EBT | -202M | -120M | -9.06M | -66.02M | -75.29M | |||||
Operating Income | -203M | -121M | -168M | -111M | -72.84M |
- Stock Market
- Stocks
- MGNX Stock
- Financials MacroGenics, Inc.
- Business Segments
Select your edition
All financial news and data tailored to specific country editions
